Description
Measure FcγRIIb Crosslinking Dependence of Agonist Antibodies
The antibodies used to stimulate T cell activation via interaction with co-stimulatory receptors on the effector cells can be crosslinked via binding to FcγRIIb receptors on aAPC/CHO-K1 cells. Based on the properties of the antibody tested, the Co-Stimulatory Immune Checkpoint (i.e., ICOS or CD28) bioassays can be conducted in a single genetically engineered cell system or dual genetically engineered cell systems.
FcγRIIb aAPC/CHO-K1 Cells are engineered to express human FcγRIIb and an engineered cell-surface protein designed to activate the TCR complex in an antigen-independent manner. They are available in thaw-and-use or Cell Propagation Model (CPM) formats. The CPM cells can be thawed, propagated and banked for long-term use. These products are not themselves reporter cells; they function to provide activation of the TCR/CD3 complex on effector cells and crosslink anti-CD28 and anti-ICOS agonist antibodies.
aAPC/CHO-K1 Cells express an engineered cell-surface protein designed to activate the TCR complex in an antigen-independent manner. They are available in thaw-and-use or Cell Propagation Model (CPM) formats. The CPM cells can be thawed, propagated and banked for long-term use. These products are not themselves reporter cells; they function to provide activation of the TCR/CD3 complex on effector cells. These cells do not express FcγRIIb.
